Cargando…

Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site

The antibiotic resistance crisis is becoming dire, yet in the past several years few potential antibiotics or adjuvants with novel modes of action have been identified. The bacterial mechanosensitive channel of large conductance, MscL, found in the majority of bacterial species, including pathogens,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wray, Robin, Wang, Junmei, Iscla, Irene, Blount, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980572/
https://www.ncbi.nlm.nih.gov/pubmed/31978161
http://dx.doi.org/10.1371/journal.pone.0228153
_version_ 1783490967683203072
author Wray, Robin
Wang, Junmei
Iscla, Irene
Blount, Paul
author_facet Wray, Robin
Wang, Junmei
Iscla, Irene
Blount, Paul
author_sort Wray, Robin
collection PubMed
description The antibiotic resistance crisis is becoming dire, yet in the past several years few potential antibiotics or adjuvants with novel modes of action have been identified. The bacterial mechanosensitive channel of large conductance, MscL, found in the majority of bacterial species, including pathogens, normally functions as an emergency release valve, sensing membrane tension upon low-osmotic stress and discharging cytoplasmic solutes before cell lysis. Opening the huge ~30Å diameter pore of MscL inappropriately is detrimental to the cell, allowing solutes from and even passage of drugs into to cytoplasm. Thus, MscL is a potential novel drug target. However, there are no known natural agonists, and small compounds that modulate MscL activity are just now being identified. Here we describe a small compound, K05, that specifically modulates MscL activity and we compare results with those obtained for the recently characterized MscL agonist 011A. While the structure of K05 only vaguely resembles 011A, many of the findings, including the binding pocket, are similar. On the other hand, both in vivo and molecular dynamic simulations indicate that the two compounds modulate MscL activity in significantly different ways.
format Online
Article
Text
id pubmed-6980572
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-69805722020-02-04 Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site Wray, Robin Wang, Junmei Iscla, Irene Blount, Paul PLoS One Research Article The antibiotic resistance crisis is becoming dire, yet in the past several years few potential antibiotics or adjuvants with novel modes of action have been identified. The bacterial mechanosensitive channel of large conductance, MscL, found in the majority of bacterial species, including pathogens, normally functions as an emergency release valve, sensing membrane tension upon low-osmotic stress and discharging cytoplasmic solutes before cell lysis. Opening the huge ~30Å diameter pore of MscL inappropriately is detrimental to the cell, allowing solutes from and even passage of drugs into to cytoplasm. Thus, MscL is a potential novel drug target. However, there are no known natural agonists, and small compounds that modulate MscL activity are just now being identified. Here we describe a small compound, K05, that specifically modulates MscL activity and we compare results with those obtained for the recently characterized MscL agonist 011A. While the structure of K05 only vaguely resembles 011A, many of the findings, including the binding pocket, are similar. On the other hand, both in vivo and molecular dynamic simulations indicate that the two compounds modulate MscL activity in significantly different ways. Public Library of Science 2020-01-24 /pmc/articles/PMC6980572/ /pubmed/31978161 http://dx.doi.org/10.1371/journal.pone.0228153 Text en © 2020 Wray et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wray, Robin
Wang, Junmei
Iscla, Irene
Blount, Paul
Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site
title Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site
title_full Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site
title_fullStr Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site
title_full_unstemmed Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site
title_short Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site
title_sort novel mscl agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980572/
https://www.ncbi.nlm.nih.gov/pubmed/31978161
http://dx.doi.org/10.1371/journal.pone.0228153
work_keys_str_mv AT wrayrobin novelmsclagoniststhatallowmultipleantibioticscytoplasmicaccessactivatethechannelthroughacommonbindingsite
AT wangjunmei novelmsclagoniststhatallowmultipleantibioticscytoplasmicaccessactivatethechannelthroughacommonbindingsite
AT isclairene novelmsclagoniststhatallowmultipleantibioticscytoplasmicaccessactivatethechannelthroughacommonbindingsite
AT blountpaul novelmsclagoniststhatallowmultipleantibioticscytoplasmicaccessactivatethechannelthroughacommonbindingsite